Are you Dr. Porteus?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
725 Welch Rd
Palo Alto, CA 94304Phone+1 650-497-8000
Summary
- Dr. Matthew Porteus, MD is a pediatric hematologist/oncologist in Palo Alto, California. He is currently licensed to practice medicine in California and Texas. He is affiliated with Lucile Packard Children's Hospital Stanford and Stanford Health Care.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1996 - 1999- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1994 - 1996
Stanford University School of MedicineClass of 1994
Certifications & Licensure
CA State Medical License 2000 - 2023
TX State Medical License 2003 - 2011- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Natural History Study of SCID Disorders Start of enrollment: 2010 Sep 02
- Patients Treated for SCID (1968-Present) Start of enrollment: 2011 May 15
- Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 Start of enrollment: 2014 Feb 02
- Join now to see all
Publications & Presentations
PubMed
- 447 citationsAn Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin LevelDaniel E. Bauer, Sophia C. Kamran, Samuel Lessard, Jian Xu, Yuko Fujiwara
Science. 2013-10-11 - 662 citationsActivation of proto-oncogenes by disruption of chromosome neighborhoodsDenes Hnisz, Abraham S. Weintraub, Daniel S. Day, Anne-Laure Valton, Rasmus O. Bak
Science. 2016-03-25 - 558 citationsIdentification of preexisting adaptive immunity to Cas9 proteins in humansCarsten T. Charlesworth, Priyanka S. Deshpande, Daniel P. Dever, Joab Camarena, Viktor T. Lemgart
Nature Medicine. 2019-01-28
Press Mentions
Transformative Stem Cell-Based Treatment for Cystic Fibrosis SinusitisJune 28th, 2024- Hit Pause: The Read-Across to Graphite Bio’s CEDAR Sickle Cell Trial SuspensionJanuary 26th, 2023
- Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell DiseaseAugust 11th, 2022
- Join now to see all
Grant Support
- Using Zinc Finger Nucleases To Stimulate Gene Targeting In HSCNational Heart, Lung, And Blood Institute2006–2009
- Zinc Finger Nucleases To Stimulate Gene Targeting In Hematopoietic Stem CellsNational Heart, Lung, And Blood Institute2007
- Development Of Gene Targeting In C. Elegans And D. Rerio Using Zinc FingerNational Cancer Institute2006–2007
- The Genetics Of Gene Targeting In Vertebrate CellsNational Heart, Lung, And Blood Institute2003–2006
- The Genetics Of Gene Targeting In Vertebrate CellsNational Heart, Lung, And Blood Institute2002
